Implanet

Based near Bordeaux (FR), IMPLANET is an international company with a US subsidiary in Boston, funded by European institutional and private investors.
Implanet focuses on spine and knee products.
Its flagship product, the JAZZ™ Band latest generation implant, is intended to improve the treatment of spinal disorders requiring spinal fusion surgery. Protected by 4 sets of international patents, JAZZ has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark.
Taking into account the evolution of the global healthcare system, the Implanet Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic and cultural specifications. The Implanet R&D team focuses on a scientifically and clinically proven implant design, using top quality materials tested to the highest prevailing standards, associated with simple and user-friendly instrumentation.
Our various workgroups, composed of surgeons, experienced engineers and product managers work closely together to offer a range of implants with scientifically sound specifications and the highest quality to adequately respond to requirements of healthcare professionals.
Implanet is able to provide the best of what science and experience have to offer, while ensuring to the stakeholders the best value for their products, their needs and demands.

Type
Public
HQ
Martillac, FR
Founded
2007
Employees
50 (est)
Implanet was founded in 2007 and is headquartered in Martillac, FR

Key People at Implanet

Stéphane MILOT

Stéphane MILOT

VP Finance & Administration
Erick CLOIX

Erick CLOIX

CEO

Implanet Locations

Martillac, FR

Implanet Metrics

Implanet Summary

Market capitalization

€8.34 M

Closing share price

€0.76
Implanet's latest market capitalization is €8.34 M.

Implanet Market Value History

Implanet Company Life